内镜技术创新在有组织结直肠癌筛查项目中检出肿瘤的作用:系统评价与荟萃分析
该系统评价与荟萃分析纳入8项高质量随机对照试验共3645例粪便免疫化学检测/粪隐血试验阳性受试者,评估内镜技术创新对腺瘤检出率的影响。干预组与标准结肠镜组的腺瘤检出率、平均每例腺瘤数、进展期腺瘤检出率、近端结肠腺瘤检出率及癌症检出率均无显著差异。作者认为这些技术创新在有组织筛查项目中不支持实施。
要点
- 在粪便免疫化学检测/粪隐血试验阳性且由高检出者行高质量结肠镜的受试者中,内镜技术创新未显著提高腺瘤检出率。
- 干预组与标准结肠镜组的平均每例腺瘤数均为1.5,无显著差异。
- 进展期腺瘤检出率、近端结肠腺瘤检出率及癌症检出率均无差异。
核心结论
- 该系统评价与荟萃分析发现,在粪便免疫化学检测阳性且由高检出者行高质量结肠镜的受试者中,没有一种技术创新显著提高结直肠肿瘤检出率,作者据此认为不支持在有组织筛查项目中实施这些技术。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、EMBASE和Cochrane Library数据库至2020年1月,纳入评估技术创新在粪便免疫化学检测/粪隐血试验阳性受试者中作用的随机对照试验。
- 共纳入8项高质量随机对照试验,3645例患者,干预组1813例(49.7%)(先进影像3项研究,机械创新5项研究),标准结肠镜组1832例(50.3%),平均年龄63.6岁。
主要发现
- 干预组汇总腺瘤检出率为56.5%(95%CI,49.9%-62.9%),标准结肠镜组为55.9%(95%CI,48.6%-63%),相对危险度(RR)为1.01(95%CI,.93-1.10;I²=50.4%)。
- 先进影像研究亚组RR为.95(95%CI,.85-1.07;I²=50.4%),机械创新研究亚组RR为1.04(95%CI,.92-1.17;I²=69.49%)。
- 干预组汇总平均每例腺瘤数为1.5(95%CI,1.2-1.8),标准结肠镜组为1.5(95%CI,1.1-1.8),未标准化均数差为.04(95%CI,-.13至.20;I²=53.6%),无显著差异。
- 进展期腺瘤检出率、近端结肠腺瘤检出率及癌症检出率均无差异。
- 未发现显著发表偏倚。
临床怎么用
- 作者认为,在粪便免疫化学检测阳性且由高检出者行高质量结肠镜的受试者中,内镜技术创新未显著提高结直肠肿瘤检出率,不支持在有组织筛查项目中实施这些技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Many endoscopic technological innovations have claimed to increase the adenoma detection rate (ADR), but their role in population-based organized screening programs is debated. METHODS: We searched PubMed, EMBASE, and Cochrane Library databases through January 2020 for randomized controlled trials (RCTs) evaluating the role of technological innovations in fecal immunochemical test (FIT)/fecal occult blood test+ subjects. The primary outcome was ADR, and secondary outcomes were advanced ADR, proximal colon ADR, mean adenoma per procedure (MAP), and cancer detection rate. We calculated pooled proportion rates (%) or risk ratio with 95% confidence interval (CI) and degree of heterogeneity (I2). RESULTS: Overall, 8 high quality RCTs met inclusion criteria with 3645 patients, 1813 (49.7%) in the intervention arm (advanced imaging, 3 studies; mechanical, 5 studies) and 1832 (50.3%) in the standard colonoscopy arm (mean age, 63.6 years). Pooled ADR was 56.5% (95% CI, 49.9%-62.9%) in the intervention arm and 55.9% (95% CI, 48.6%-63%) in the standard colonoscopy arm (relative risk [RR], 1.01; 95% CI, .93-1.10; I2 = 50.4%). Similarly, no difference was observed for advanced imaging studies (RR, .95; 95% CI, .85-1.07; I2 = 50.4%) or those with mechanical innovations (RR, 1.04; 95% CI, .92-1.17; I2 = 69.49%). The pooled MAP was 1.5 in the intervention arm (95% CI, 1.2-1.8) and 1.5 in the standard colonoscopy (95% CI, 1.1-1.8), with no significant difference (unstandardized mean difference, .04; 95% CI, -.13 to .20; I2 = 53.6%). No difference in advanced ADR, proximal colon ADR, or cancer detection was found. No significant publication bias was found. CONCLUSIONS: In our systematic review and meta-analysis, no technological improvement significantly increased detection rate of colorectal neoplasia in FIT+ subjects undergoing high-quality colonoscopy by high detectors, arguing against their implementation in organized programs.
引用
- Thayalasekaran S, Frazzoni L, Antonelli G, et al. Endoscopic technological innovations for neoplasia detection in organized colorectal cancer screening programs: a systematic review and meta-analysis. Gastrointest Endosc. 2020. PMID: 32590053. doi:10.1016/j.gie.2020.06.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。